Loading stock data…
AUTL
$1.57-0.04 (-2.18%)
Market ClosedLast close May 8
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Autolus Therapeutics plc in the Healthcare sector is trading at $1.57. The stock is currently 42% below its 52-week high of $2.70, remaining 1.3% below its 200-day moving average. Technical signals show neutral RSI of 49 and bullish MACD crossover, explaining why AUTL maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 49) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.57
Potential Upside
5%
Whystock Fair Value$1.65
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company's clinical-stage programs include obecabtagene ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$425.83M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-161.42%
Volume
Today's trading volume
1.20M
Recent News
European Equities Traded in the US as American Depositary Receipts Heading Lower in Thursday Trading
European equities traded in the US as American depositary receipts were tracking lower late Thursday
3 Promising Penny Stocks With Market Caps Up To $900M
The market remained flat over the last week, yet it is up 28% over the past year with earnings expected to grow by 16% per annum in the coming years. In this context, identifying stocks that combine solid financials with growth potential is crucial for investors looking to capitalize on market opportunities. Penny stocks, often associated with smaller or newer companies, continue to be relevant as they can offer significant returns when backed by strong fundamentals.
How The Narrative On Autolus Therapeutics (AUTL) Is Shifting After Analyst Target Resets
Analysts have recently trimmed their price targets on Autolus Therapeutics by about $2 to $3 per share, while the model fair value estimate remains at $8.81 per share. Some interpret these lower targets as a recalibration of expectations rather than a shift in conviction, while others view them as a caution flag around execution, funding risk, and the timing of profitability. As you read on, you will see how to track these evolving views and what to watch as the story develops. Stay updated...
European Equities Traded in the US as American Depositary Receipts Start Week Lower
European equities traded in the US as American depositary receipts kicked off the week lower late Mo
Is Autolus Therapeutics (AUTL) One of the Best Biotech Penny Stocks to Buy in 2026?
Autolus Therapeutics plc (NASDAQ:AUTL) is one of the best biotech penny stocks to buy in 2026. On March 27, Autolus Therapeutics reported Q4 and full-year 2025 financial results, highlighting the commercial scale-up of its CAR T-cell therapy, AUCATZYL. The company achieved net product revenue of $74.3 million for 2025, with $23.3 million generated in Q4. […]